Form 4: Day One Biopharmaceuticals CEO Jeremy Bender Executes Stock Transactions

Day One Biopharmaceuticals CEO Jeremy Bender acquired shares through RSU vesting and sold some to cover tax obligations.

Summary

• Jeremy Bender, CEO of Day One Biopharmaceuticals, engaged in multiple transactions involving the company's stock.
• On November 15, 2024, Bender acquired 3,562, 4,750, and 11,687 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• These RSUs were converted into common stock at no cost.
• On November 18, 2024, Bender sold 10,554 shares at a weighted average price of $13.2102 per share.
• The sale was solely to cover tax liabilities associated with the RSU vesting.
• Bender also holds a significant number of shares indirectly through various trusts.
• These trusts include The Jeremy Bender 2022 and 2023 Grantor Retained Annuity Trusts, The Melissa Bender 2022 and 2023 Grantor Retained Annuity Trusts, and the Bender Revocable Trust.

Sentiment

Score: 6

Explanation: The document reflects routine transactions related to executive compensation. While the sale of shares might cause minor concern, it's primarily for tax purposes and is not indicative of a negative outlook. The indirect holdings through trusts are common and do not raise immediate red flags.

Positives

• The vesting of RSUs indicates a form of compensation and alignment of interests between the CEO and the company.
• The sale of shares was explicitly for tax obligations, which is a common practice.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors as a reduction in the CEO's direct holdings.

Risks

• The market may react to the sale of shares, even if for tax purposes, potentially causing short-term price fluctuations.
• The complex structure of indirect holdings through multiple trusts could raise questions about transparency.

Industry Context

This is a standard SEC Form 4 filing, which is common for company executives who trade their company's stock. The transactions are typical for executives receiving stock-based compensation.

Comparison to Industry Standards

• The vesting of RSUs and subsequent sale to cover taxes is a common practice among executives in publicly traded companies.
• Many biotech companies use RSUs as part of their compensation packages to align executive interests with shareholder value.
• The use of trusts for holding shares is also a common strategy for estate planning and tax management among high-net-worth individuals, including executives.

Stakeholder Impact

• Shareholders may have a neutral to slightly negative reaction to the sale of shares, even if for tax purposes.
• Employees may see the RSU vesting as a positive sign of the company's compensation practices.

Key Dates

Keywords

stock transactions, insider trading, RSU, restricted stock units, Jeremy Bender, Day One Biopharmaceuticals, executive compensation, Form 4, share sale, trusts